CoChat

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set

Open access
Roszik, Jason, Haydu, Lauren E., Hess, Kenneth R., Oba, Junna, Joon, Aron Y., Siroy, Alan E., Karpinets, Tatiana V., Stingo, Francesco C., Baladandayuthapani, Veera, Tetzlaff, Michael T., Wargo, Jennifer A., Chen, Ken, Forget, Marie-Andrée, Haymaker, Cara L., Chen, Jie Qing, Meric-Bernstam, Funda, Eterovic, Agda K., Shaw, Kenna R., Mills, Gordon B., Gershenwald, Jeffrey E., Radvanyi, Laszlo G., Hwu, Patrick, Futreal, P. Andrew, Gibbons, Don L., Lazar, Alexander J., Bernatchez, Chantale, Davies, Michael A., Woodman, Scott E. · 2016 · BMC Medicine
Cited by 115

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND: While clinical outcomes following immunotherapy have shown an association with tumor mutation load using whole exome sequencing (WES), its clinical applicability is currently limited by cost and bioinformatics requirements. METHODS: We developed a method to accurately derive the predicted total mutation load (PTML) within individual tumors from a small set of genes that can be used in clinical next generation sequencing (NGS) panels. PTML was derived from the actual total mutation load (ATML) of 575 distinct melanoma and lung cancer samples and validated using independent melanoma (n = 312) and lung cancer (n = 217) cohorts. The correlation of PTML status with clinical outcome, following distinct immunotherapies, was assessed using the Kaplan-Meier method. RESULTS: = 0.82, respectively). PTML was strongly associated with clinical outcome to ipilimumab (anti-CTLA-4, three cohorts) and adoptive T-cell therapy (1 cohort) clinical outcome in melanoma. Clinical benefit from pembrolizumab (anti-PD-1) in lung cancer was also shown to significantly correlate with PTML status (log rank P value < 0.05 in all cohorts). CONCLUSIONS: The approach of using small NGS gene panels, already applied to guide employment of targeted therapies, may have utility in the personalized use of immunotherapy in cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-016-0705-4

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 115

Metadata

Authors
Roszik, J., Haydu, L. E., Hess, K. R., Oba, J., Joon, A. Y., Siroy, A. E., Karpinets, T. V., Stingo, F. C., Baladandayuthapani, V., Tetzlaff, M. T., Wargo, J. A., Chen, K., Forget, M.-A., Haymaker, C. L., Chen, J. Q., Meric-Bernstam, F., Eterovic, A. K., Shaw, K. R., Mills, G. B., Gershenwald, J. E., Radvanyi, L. G., Hwu, P., Futreal, P. A., Gibbons, D. L., Lazar, A. J., Bernatchez, C., Davies, M. A., & Woodman, S. E.
Venue
BMC Medicine
Published
2016-10-25
Volume
14
Issue
1
Pages
168-168
ISSN
1741-7015 (ISSN-L)
OpenAlex
W2539418106
Cited by
115
References
10
FWCI
9.27
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. https://app.cochat.ai/papers/10.1186/s12916-016-0705-4
The paper
Roszik, J., Haydu, L. E., Hess, K. R., Oba, J., Joon, A. Y., Siroy, A. E., Karpinets, T. V., Stingo, F. C., Baladandayuthapani, V., Tetzlaff, M. T., Wargo, J. A., Chen, K., Forget, M.-A., Haymaker, C. L., Chen, J. Q., Meric-Bernstam, F., Eterovic, A. K., Shaw, K. R., Mills, G. B., . . . Woodman, S. E. (2016). Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine. https://doi.org/10.1186/s12916-016-0705-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.